{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Grade 1"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Grade 2"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"Grade 3"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Not graded"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"G1 - Highly differentiated adenomatous carcinoma. G2 - Differentiated adenomatous carcinoma with partly solid areas. G3 - Predominantly solid or entirely undifferentiated carcinoma. Not graded - tumor grade not reported.","groups":[{"description":"Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Gleevec"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Initial Histologic Grade","type":"SECONDARY","unitOfMeasure":"Participants"}